Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

Y0001601

Alfacalcidol for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1α-Hydroxyvitamin D3, 1α-Hydroxycholecalciferol, Alfacalcidol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C27H44O2
CAS Number:
41294-56-8
Molecular Weight:
400.64
MDL number:
MFCD00868328
UNSPSC Code:
41116107
PubChem Substance ID:
329831506
NACRES:
NA.24

biological source

synthetic

grade

pharmaceutical primary standard

Agency

EP

form

solid

manufacturer/tradename

EDQM

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1

InChI key

OFHCOWSQAMBJIW-AVJTYSNKSA-N

Gene Information

human ... VDR(7421)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Synthetic vitamin D3 analog that is metabolized to 1,25-dihydroxycholecalciferol. Inhibits bone resorption and stimulates bone formation. Supresses parathyroid hormone secretion by bovine parathyroid cells.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H300

Precautionary Statements

P301 + P330 + P331 + P310

Hazard Classifications

Acute Tox. 1 Oral

Storage Class Code

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

Y0001601:
Y0001601-1EA:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vitamin D and metabolites measurement by tandem mass spectrometry
van den Ouweland JMW, et al.
Reviews in Endocrine & Metabolic Disorders, 14(2), 159-184 (2013)
Novel approach for the determination of alfacalcidol in bulk and tablet dosage form using spectrophotometric method
Saeed-Ul-Hassan S, et al.
Latin American Journal of Pharmacy, 32(5), 784-788 (2013)
The use of alfacalcidol in the prevention of bone disease in early renal failure.
J A Kanis
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 10 Suppl 4, 23-28 (1995-01-01)
Ayako Shiraishi et al.
The Journal of steroid biochemistry and molecular biology, 144 Pt A, 119-123 (2013-11-06)
Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, is a potent inhibitor of bone resorption that has demonstrated a greater effect at reducing the risk of fracture in osteoporotic patients than alfacalcidol (ALF). In the present study, we used the senescence-accelerated
E Schacht
Calcified tissue international, 65(4), 317-327 (1999-09-15)
Increased cytokine release and increased activity of osteoclasts (reduced osteoclast apoptosis) due to a fall in estrogen is of causal significance in postmenopausal bone loss as well as malfunction of the vitamin D activation and concomitant calcium (Ca) malabsorption. Alfacalcidol
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service